Cargando…
Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma
BACKGROUND: miRNAs are involved in tumor pathogenesis and can therefore be determined in the primary tumor, plasma and serum, and body fluids. As in various cancers, their role in the diagnosis, prognosis, and treatment of patients with malignant pleural mesothelioma (MPM) may be important. AIMS: To...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326946/ https://www.ncbi.nlm.nih.gov/pubmed/35695486 http://dx.doi.org/10.4274/balkanmedj.galenos.2022.2022-3-26 |
_version_ | 1784757403362787328 |
---|---|
author | Metintaş, Muzaffer Ak, Güntülü Özbayer, Cansu Boğar, Filiz Metintaş, Selma |
author_facet | Metintaş, Muzaffer Ak, Güntülü Özbayer, Cansu Boğar, Filiz Metintaş, Selma |
author_sort | Metintaş, Muzaffer |
collection | PubMed |
description | BACKGROUND: miRNAs are involved in tumor pathogenesis and can therefore be determined in the primary tumor, plasma and serum, and body fluids. As in various cancers, their role in the diagnosis, prognosis, and treatment of patients with malignant pleural mesothelioma (MPM) may be important. AIMS: To analyze the predictive value of miR-16-5p, miR-29c-3p, miR-31-5p, miR-125a-5p, miR-320a, miR-484 and miR-532-5p expressions for diagnosis, prognosis and response to treatment in patients with MPM. STUDY DESIGN: Prospective case-control study. METHODS: In the first phase of the study, blood samples were collected from 101 MPM patients before chemotherapy and from 24 healthy donors (HDs). In the second phase, the blood samples were collected from 74 MPM patients who had received chemotherapy when the best overall response and disease recurrence were determined. A quantitative real-time polymerase chain reaction was undertaken to detect the miRNA expression levels. The miRNA expression profiles of MPM patients were compared with those of HDs. The associations between the expression levels of miRNAs and prognosis and response to treatment were then evaluated. RESULTS: All miRNAs, except miR-31-5p, were expressed differently in MPM relative to that in HDs. The expression level of miR-16-5p decreased when compared with that of HDs, and the expression levels of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p increased when compared with that of HDs. The sensitivity and specificity values of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p for discriminating MPM from HDs were 85.9% and 59.1%, 95.1% and 62.5%, 87.1% and 79.2%, 82.2% and 58.3%, and 69.3% and 82.6%, respectively. After adjusting for the histological subtype, stage, and treatment, the miR-29c-3p, miR-125a-5p, and miR-484 were associated with longer survival. The miRNA expression levels did not change longitudinally for the determination of chemotherapy response and recurrence. CONCLUSION: miRNAs may be useful in diagnosing patients with MPM and provides helpful information in determining the prognosis of patients. |
format | Online Article Text |
id | pubmed-9326946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-93269462022-08-09 Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma Metintaş, Muzaffer Ak, Güntülü Özbayer, Cansu Boğar, Filiz Metintaş, Selma Balkan Med J Original Article BACKGROUND: miRNAs are involved in tumor pathogenesis and can therefore be determined in the primary tumor, plasma and serum, and body fluids. As in various cancers, their role in the diagnosis, prognosis, and treatment of patients with malignant pleural mesothelioma (MPM) may be important. AIMS: To analyze the predictive value of miR-16-5p, miR-29c-3p, miR-31-5p, miR-125a-5p, miR-320a, miR-484 and miR-532-5p expressions for diagnosis, prognosis and response to treatment in patients with MPM. STUDY DESIGN: Prospective case-control study. METHODS: In the first phase of the study, blood samples were collected from 101 MPM patients before chemotherapy and from 24 healthy donors (HDs). In the second phase, the blood samples were collected from 74 MPM patients who had received chemotherapy when the best overall response and disease recurrence were determined. A quantitative real-time polymerase chain reaction was undertaken to detect the miRNA expression levels. The miRNA expression profiles of MPM patients were compared with those of HDs. The associations between the expression levels of miRNAs and prognosis and response to treatment were then evaluated. RESULTS: All miRNAs, except miR-31-5p, were expressed differently in MPM relative to that in HDs. The expression level of miR-16-5p decreased when compared with that of HDs, and the expression levels of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p increased when compared with that of HDs. The sensitivity and specificity values of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p for discriminating MPM from HDs were 85.9% and 59.1%, 95.1% and 62.5%, 87.1% and 79.2%, 82.2% and 58.3%, and 69.3% and 82.6%, respectively. After adjusting for the histological subtype, stage, and treatment, the miR-29c-3p, miR-125a-5p, and miR-484 were associated with longer survival. The miRNA expression levels did not change longitudinally for the determination of chemotherapy response and recurrence. CONCLUSION: miRNAs may be useful in diagnosing patients with MPM and provides helpful information in determining the prognosis of patients. Galenos Publishing 2022-07-22 /pmc/articles/PMC9326946/ /pubmed/35695486 http://dx.doi.org/10.4274/balkanmedj.galenos.2022.2022-3-26 Text en ©Copyright 2022 by Trakya University Faculty of Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Balkan Medical Journal published by Galenos Publishing House. |
spellingShingle | Original Article Metintaş, Muzaffer Ak, Güntülü Özbayer, Cansu Boğar, Filiz Metintaş, Selma Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma |
title | Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma |
title_full | Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma |
title_fullStr | Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma |
title_full_unstemmed | Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma |
title_short | Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma |
title_sort | serum expression levels of certain mirnas in predicting diagnosis, prognosis, and response to chemotherapy in malignant pleural mesothelioma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326946/ https://www.ncbi.nlm.nih.gov/pubmed/35695486 http://dx.doi.org/10.4274/balkanmedj.galenos.2022.2022-3-26 |
work_keys_str_mv | AT metintasmuzaffer serumexpressionlevelsofcertainmirnasinpredictingdiagnosisprognosisandresponsetochemotherapyinmalignantpleuralmesothelioma AT akguntulu serumexpressionlevelsofcertainmirnasinpredictingdiagnosisprognosisandresponsetochemotherapyinmalignantpleuralmesothelioma AT ozbayercansu serumexpressionlevelsofcertainmirnasinpredictingdiagnosisprognosisandresponsetochemotherapyinmalignantpleuralmesothelioma AT bogarfiliz serumexpressionlevelsofcertainmirnasinpredictingdiagnosisprognosisandresponsetochemotherapyinmalignantpleuralmesothelioma AT metintasselma serumexpressionlevelsofcertainmirnasinpredictingdiagnosisprognosisandresponsetochemotherapyinmalignantpleuralmesothelioma |